Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

You may also be interested in...



Keeping Track: A Quintet Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker. 

CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018

Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.

GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'

GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel